Biologics register JuMBO: Long-term safety of biologic therapy of juvenile idiopathic arthritis;Biologikaregister JuMBO: Langzeitsicherheit von Biologikatherapie bei juveniler idiopathischer Arthritis

Zeitschrift fur Rheumatologie

Volumn 72, Issue 4, 2013, Pages 339-346

  Minden, K ^a,b   Klotsche, J ^a   Niewerth, M ^a   Horneff, G ^c   Zink, A ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Asklepios Kinderklinik St Augustin GmbH   (Germany)

Author keywords

Biologics; Drug safety; Etanercept; Long term outcome; Long term safety

Indexed keywords

ETANERCEPT; METHOTREXATE;

ARTICLE; BIOLOGICAL THERAPY; DRUG SAFETY; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; PATIENT SAFETY; TREATMENT DURATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN G; MALE; PREVALENCE; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877744908     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-012-1063-z     Document Type: Article

References (27)

1. Beukelman T, Haynes K, Curtis JR et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:1263-1271
2. Diak P, Siegel J, La Grenade L et al (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the food and drug administration. Arthritis Rheum 62:2517-2524
3. Flatø B, Lien G, Smerdel A et al (2003) Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 30:386-393
4. Foster HE, Marshall N, Myers A et al (2003) Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 48:767-775
5. Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137-145
6. Giannini EH, Ilowite NT, Lovell DJ et al (2009) Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 60:2794-2804
7. Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63:1638-1644
8. Horneff G, Foeldvari I, Minden K et al (2011) Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 50:230-236
9. Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763-769
10. Lovell DJ, Reiff A, Ilowite NT et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496-1504
11. Lovell DJ, Ruperto N, Goodman S et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810-820
12. Minden K, Niewerth M, Listing J et al (2002) Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46:2392-2401
13. Nordstrom BL, Mines D, Gu Y et al (2012) Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Arthritis Care Res (Hoboken) 64:1357-1364
14. Oen K, Malleson PN, Cabral DA et al (2002) Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 29:1989-1999
15. Otten MH, Prince FHM, Armbrust W et al (2011) Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 306:2340-2347
16. Packham JC, Hall MA (2002) Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 41:1428-1435
17. Petty RE, Southwood TR, Manners P et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390-392
18. Prince FHM, Twilt M, ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68:635-641
19. Robert-Koch-Institute (1998) Public use file. National Health Survey
20. Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383-391
21. Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792-1802
22. Sevcic K, Orban I, Brodszky V et al (2011) Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology (Oxford) 50:1337-1340
23. Simard JF, Neovius M, Hagelberg S, Askling J (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62:3776-3782
24. Dijken TD van, Vastert SJ, Gerloni VM et al (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38:1441-1446
25. Wallace CA, Ruperto N, Giannini E (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31:2290-2294
26. Ware J, Snow K, Kosinski M (1997) SF-36 health survey. Manual and interpretation guide. The National Health Institute, New England Medical Center, Boston
27. Zink A, Listing J, Strangfeld A et al (2006) Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT. Z Rheumatol 65:441-446